NewcelX Ltd.
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Market Cap & Net Worth: NewcelX Ltd. (NCEL)
NewcelX Ltd. (NASDAQ:NCEL) has a market capitalization of $25.37K ($25.37K) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #43384 globally and #13889 in its home market, demonstrating a -1.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NewcelX Ltd.'s stock price $2.69 by its total outstanding shares 9433 (9.43K).
NewcelX Ltd. Market Cap History: 2025 to 2026
NewcelX Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $17.92K to $25.37K (0.00% CAGR).
NewcelX Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NewcelX Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NCEL by Market Capitalization
Companies near NewcelX Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to NewcelX Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NewcelX Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, NewcelX Ltd.'s market cap moved from $17.92K to $ 25.37K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.37K | +41.58% |
| 2025 | $17.92K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NewcelX Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.37K USD |
| MoneyControl | $25.37K USD |
| MarketWatch | $25.37K USD |
| marketcap.company | $25.37K USD |
| Reuters | $25.37K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.